CDK9 and T-cell non-Hodgkin lymphoma: As selective CDK9 inhibitors are currently being investigated in multiple cancers [39, 40], and prior screening efforts have suggested that CDK9 is a potential therapeutic vulnerability in T-cell lymphomas [41, 42], we sought to examine its role in regulating oncogenic transcriptional programs in the T-cell lymphomas.